Faster global financial news!
Gilead Sciences
-
Gilead Sciences (GILD) received its third FDA approval in less than four months, with the latest being Bixlenvo approved on August 27 for the treatment of HIV-infected individuals.
Gilead Sciences has secured three U.S. Food and Drug Administration (FDA) approvals in less than four months. The most recent, on August 27, was for Bixlenvo as a daily oral medication for the treatme
-
Gilead Sciences' Q2 revenue increased by 10% year-over-year to $7.8 billion, but due to acquisition-related R&D expenses, it recorded a loss of $8.45 per share.
Gilead Sciences (GILD) announced its second-quarter fiscal year 2026 results, with total revenue increasing by 10% year-over-year to approximately $7.8 billion, and product sales growing by 8% to $7.6
-
Analysis indicates that Walmart, McDonald's, and Gilead Sciences outperformed the S&P 500 during market downturns in 2008 and 2022.
An analysis article from Yahoo Finance points out that, against the backdrop of a potential market pullback, three US stocks—Walmart (WMT), McDonald's (MCD), and Gilead Sciences (GILD)—have demonstrat
-
Gilead Sciences (GILD) received its third FDA approval in less than four months, with the latest being Bixlenvo approved on August 27 for the treatment of HIV-infected individuals.
Gilead Sciences has secured three U.S. Food and Drug Administration (FDA) approvals in less than four months. The most recent, on August 27, was for Bixlenvo as a daily oral medication for the treatme
-
Gilead Sciences' Q2 revenue increased by 10% year-over-year to $7.8 billion, but due to acquisition-related R&D expenses, it recorded a loss of $8.45 per share.
Gilead Sciences (GILD) announced its second-quarter fiscal year 2026 results, with total revenue increasing by 10% year-over-year to approximately $7.8 billion, and product sales growing by 8% to $7.6
-
Analysis indicates that Walmart, McDonald's, and Gilead Sciences outperformed the S&P 500 during market downturns in 2008 and 2022.
An analysis article from Yahoo Finance points out that, against the backdrop of a potential market pullback, three US stocks—Walmart (WMT), McDonald's (MCD), and Gilead Sciences (GILD)—have demonstrat
- No data
Gilead Sciences
24H Trending
-
1
Oasys (OAS) Project Analysis: The Intersection of Gaming Chains and On-Chain Perpetual Contracts
-
2
Crypto market enters October after strong Q3, eyes Ethereum testnet and ETF flows
-
3
RSS3: Web3 Decentralized Information Protocol and Its Token Analysis
-
4
HAN Token Analysis: What is HanChain? How to Trade and Acquire It?
-
5
ENJ Trading Guide: How to Buy and Sell Enjin Tokens and Their Listed Exchanges
-
6
OKX Exchange Reliability Analysis and Latest Developments
-
7
Can Cryptocurrencies Be Transferred Immediately After Purchase? Platform and Process Analysis
-
8
YFC (Yearnchange) Token Analysis: The Current State and Risks of DeFi Copycats
-
9
ILV Token and Chainlink: Deep Integration and Innovative Potential in the Illuvium Blockchain Game
-
10
THORChain's Recent Security Incidents: Multi-Million Dollar Losses and RUNE Price Volatility
Markets Today
Recommended Reading
Hot Topics
Svmuu focuses on blockchain industry trends and cutting-edge cryptocurrency news, while also covering real-time market data and in-depth analysis of the Hong Kong, U.S., and foreign exchange markets. Here, you can not only access professional 24/7 news updates and accurate market data, but also utilize practical investment tools to help you capitalize on opportunities in both digital assets and traditional financial markets. Whether you are a blockchain enthusiast or an investor in Hong Kong, U.S., or foreign exchange markets, we provide efficient and timely information services to empower your investment decisions.
- User Agreement
- Privacy Policy
- Contact Us
- Business Partnerships
- Disclaimer
- Content Statement
- About Us
- Sitemap
Coming Soon!
